Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.55 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267206 | 0.91 | MAP2K1 (0.68) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6262646 | 0.90 | MEN1 (0.68) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6264227 | 0.88 | MEN1 (0.64) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6262850 | 0.86 | MEN1 (0.62) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL1801637 | 0.86 | MEN1 (1.00) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL29356577 | 0.86 | MEN1 (1.00) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6266866 | 0.85 | MEN1 (0.61) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6834310 | 0.85 | MEN1 (0.61) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6263997 | 0.85 | MEN1 (0.70) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6261447 | 0.85 | MEN1 (0.70) | MEN1KMT2ATDP1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144371-B1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6750217-B2 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS; KINASE INHIBITOR | WARNER-LAMBERT COMPANY | 2004-06-15 | — | — | US | disclosed |
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2003-05-15 | — | — | US | disclosed |
| US-6440966-B1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | NR2E1, NR0B1, NR0B2 | MEN1 3092/4885KMT2A 2782/4885TDP1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.